X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DIVIS LABORATORIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DIVIS LABORATORIES TORRENT PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 36.7 31.9 115.0% View Chart
P/BV x 5.7 5.2 110.4% View Chart
Dividend Yield % 1.0 1.0 99.5%  

Financials

 TORRENT PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
DIVIS LABORATORIES
Mar-17
TORRENT PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7681,222 144.7%   
Low Rs1,186784 151.2%   
Sales per share (Unadj.) Rs346.1153.1 226.1%  
Earnings per share (Unadj.) Rs55.239.9 138.1%  
Cash flow per share (Unadj.) Rs73.344.6 164.4%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %0.91.0 95.1%  
Book value per share (Unadj.) Rs257.1201.8 127.4%  
Shares outstanding (eoy) m169.22265.47 63.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.36.6 65.1%   
Avg P/E ratio x26.825.1 106.6%  
P/CF ratio (eoy) x20.122.5 89.6%  
Price / Book Value ratio x5.75.0 115.6%  
Dividend payout %25.425.0 101.4%   
Avg Mkt Cap Rs m249,887266,266 93.8%   
No. of employees `00011.89.7 121.0%   
Total wages/salary Rs m9,9344,687 211.9%   
Avg. sales/employee Rs Th4,971.54,175.0 119.1%   
Avg. wages/employee Rs Th843.2481.5 175.1%   
Avg. net profit/employee Rs Th792.41,089.3 72.7%   
INCOME DATA
Net Sales Rs m58,56940,643 144.1%  
Other income Rs m2,233749 298.2%   
Total revenues Rs m60,80241,392 146.9%   
Gross profit Rs m13,77314,460 95.2%  
Depreciation Rs m3,0691,233 248.9%   
Interest Rs m2,05623 9,095.6%   
Profit before tax Rs m10,88113,953 78.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5453,349 46.1%   
Profit after tax Rs m9,33610,604 88.0%  
Gross profit margin %23.535.6 66.1%  
Effective tax rate %14.224.0 59.2%   
Net profit margin %15.926.1 61.1%  
BALANCE SHEET DATA
Current assets Rs m53,84140,105 134.2%   
Current liabilities Rs m31,6126,595 479.4%   
Net working cap to sales %38.082.5 46.0%  
Current ratio x1.76.1 28.0%  
Inventory Days Days97119 82.0%  
Debtors Days Days8481 103.8%  
Net fixed assets Rs m42,07919,995 210.4%   
Share capital Rs m846531 159.4%   
"Free" reserves Rs m42,65553,043 80.4%   
Net worth Rs m43,50153,574 81.2%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25061,585 164.4%  
Interest coverage x6.3618.4 1.0%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.7 87.7%   
Return on assets %11.317.3 65.2%  
Return on equity %21.519.8 108.4%  
Return on capital %19.626.1 75.2%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m20,06635,384 56.7%   
Fx outflow Rs m5,30410,399 51.0%   
Net fx Rs m14,76224,985 59.1%   
CASH FLOW
From Operations Rs m10,12711,493 88.1%  
From Investments Rs m-7,869-11,372 69.2%  
From Financial Activity Rs m-1,918-93 2,060.2%  
Net Cashflow Rs m21228 744.7%  

Share Holding

Indian Promoters % 71.5 52.0 137.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.8 59.5%  
FIIs % 12.6 19.0 66.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.2 51.2%  
Shareholders   26,511 31,796 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS